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ABSTRACT
Expression of the scaffolding protein Caveolin-1 (CAV1) enhances migration and 
invasion of metastatic cancer cells. Yet, CAV1 also functions as a tumor suppressor 
in early stages of cancer, where expression is suppressed by epigenetic mechanisms. 
Thus, we sought to identify stimuli/mechanisms that revert epigenetic CAV1 silencing 
in cancer cells and evaluate how this affects their metastatic potential. We reasoned 
that restricted tissue availability of anti-neoplastic drugs during chemotherapy might 
expose cancer cells to sub-therapeutic concentrations, which activate signaling 
pathways and the expression of CAV1 to favor the acquisition of more aggressive 
traits. Here, we used in vitro [2D, invasion] and in vivo (metastasis) assays, as well as 
genetic and biochemical approaches to address this question. Colon and breast cancer 
cells were identified where CAV1 levels were low due to epigenetic suppression and 
could be reverted by treatment with the methyltransferase inhibitor 5’-azacytidine. 
Exposure of these cells to anti-neoplastic drugs for short periods of time (24-48 h) 
increased CAV1 expression through ROS production and MEK/ERK activation. In colon 
cancer cells, increased CAV1 expression enhanced migration and invasion in vitro via 
pathways requiring Src-family kinases, as well as Rac-1 activity. Finally, elevated 
CAV1 expression in colon cancer cells following exposure in vitro to sub-cytotoxic 
drug concentrations increased their metastatic potential in vivo. Therefore exposure 
of cancer cells to anti-neoplastic drugs at non-lethal drug concentrations induces 
signaling events and changes in transcription that favor CAV1-dependent migration, 
invasion and metastasis. Importantly, this may occur in the absence of selection for 
drug-resistance.
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INTRODUCTION
Caveolin-1 (CAV1) is an integral membrane protein 
that plays a dual role in tumor progression [1, 2]. On the 
one hand, CAV1 protein and mRNA levels are decreased 
in transformed fibroblasts and in breast and colon cancer 
cell lines. Also, CAV1 reduction in normal cells promotes 
cell transformation [3, 4]. Moreover, levels of CAV1 
are reduced in several human tumors and, in these cells, 
CAV1 re-expression is often sufficient to block functions 
associated with the transformed cell phenotype [2, 5]. 
Available evidence indicates that CAV1 down-regulation, 
observed upon cell transformation, is due to CAV1 gene 
silencing by methylation of CG nucleotide enriched 
sequences (CpG islands) present in the caveolin-1 
promoter region. These CpG islands are not methylated 
in normal breast epithelial cells that express higher levels 
of CAV1; however in breast cancer cell lines that do not 
express CAV1, this region is highly methylated [6].
Alternatively, at later stages of cancer, CAV1 re-
expression in lung adenocarcinoma, promotes filopodia 
formation and increases cell migration, as well as 
metastatic potential [7]. In breast cancer cell lines and 
melanomas, CAV1 expression favors focal adhesion 
turnover, cell migration and metastasis [8]. The increased 
levels of CAV1 have been associated with multidrug 
resistance (MDR) [9–11]. In HT29 colon cancer cells, 
resistance to the anti-neoplastic drug Methotrexate 
correlates with higher levels of CAV1 in comparison to 
untreated cells [1, 12] and silencing of CAV1 expression 
by RNA interference decreases the MDR phenotype and 
sensitizes cells to Methotrexate treatment [13].
Therefore, given the existing connection between 
elevated CAV1 expression and drug resistance, and the 
fact that different stress situations are known to augment 
CAV1 expression, we hypothesized that treatment with 
anti-neoplastic drugs at sub-cytotoxic doses may suffice to 
increase CAV1 levels in cancer cells where the caveolin-1 
gene was silenced epigenetically.
Cancer cells are known to possess higher levels of 
endogenous reactive oxygen species (ROS) than healthy 
cells, due to the decreased oxygen levels or hypoxia 
in the tumor microenvironment, enhanced cellular 
metabolism, mitochondrial dysfunction, increased 
growth factor receptor-mediated signaling and oncogene 
activity [14–18]. For this reason, one of the frequently 
employed strategies to kill cancer cells is by treatment 
with chemotherapeutic drugs that increase ROS levels 
beyond the adaptive threshold, which is lower in tumor 
cells than normal cells, thus triggering apoptosis [19–22]. 
However, the induction of ROS production by these 
chemotherapeutic agents can also activate proliferative 
and pro-survival signaling pathways, involving ERK1/2 
and AKT. Activation of these pathways may favor the 
development of malignant characteristics, including 
increased cell migration associated with an elevated 
metastatic potential in cancer cells [23, 24]. Metastasis 
involves several steps, including degradation of the 
extracellular matrix, stromal invasion, intravasation to 
blood vessels, extravasation, migration and proliferation 
in other tissues and organs [25, 26] CAV1 interacts with 
proteins required for cell migration, such as β1 integrin 
[27] and filamin, promoting lamellipodia formation 
[28] and migration of fibroblasts in a RhoA-dependent 
fashion [29]. Alternatively, CAV1 promotes migration 
of metastatic breast cancer (MDA-MB-231), colon 
cancer (HT29(US)) and melanoma (B16F10, A375M) 
cells via activation of the Rab5-Rac1 signaling axis [2, 
30, 31]. Increased CAV1 expression and particularly its 
phosphorylation on Y14 by Src family kinases are essential 
to enhance cell migration, invasion and anchorage-
independent growth [32]. Importantly, in metastatic MDA-
MB-231 cells, CAV1 is highly phosphorylated on Y14 
in comparison with non-metastatic cancer cells [32] and 
in B16F10 melanoma cells CAV1 expression promotes 
matrix-specific migration, invasion and trans-endothelial 
migration in a Y14-dependent manner [33].
Given these attributes of CAV1, we evaluated the 
possibility that acute treatments of cancer cells with 
anti-neoplastic drugs could increase CAV1 expression. 
We also determined the signaling pathways involved in 
this up-regulation and the functional consequences of 
CAV1 re-expression in cancer cells were assessed using 
both in vitro and in vivo approaches. A DNA methylation 
inhibitor restored subdued basal CAV1 expression in 
colon and breast cancer cells. Additionally, Methotrexate 
and Etoposide decreased promoter region methylation, 
as well as increased CAV1 mRNA and protein levels in 
a MEK/ERK and ROS-dependent manner. Importantly, 
elevated CAV1 levels observed following drug exposure 
were associated with increased presence of tumor cells in 
ascites and metastasis in vivo. Finally, down-regulation 
of CAV1 using specific short hairpin RNA (shRNA) 
constructs sufficed to reverse these drug-induced effects, 
both in vitro and in vivo.
Taken together, these results implicate acutely 
enhanced CAV1 expression following the treatment with 
anti-neoplastic drugs at sub-cytotoxic concentrations in 
promoting the acquisition of malignant traits associated 
with a more aggressive cancer cell phenotype.
RESULTS
CAV1 expression is suppressed by methylation 
rather than histone acetylation in colon and 
breast cancer cell lines
The 5’ region of the caveolin-1 promoter is 
enriched in CpG islands that are methylated in breast, 
lung, ovarian and colon cancer cell lines [5, 6, 34, 35]. 
We have previously shown in colon cancer cell lines that 
increased CAV1 expression arises in conjunction with 
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the development of drug-resistance [2]. At least, two 
potential hypotheses may be entertained to explain these 
observations. One is that exposure to chemotherapeutic 
drugs selects for cells that are drug-resistant and that 
these express higher CAV1 levels. Alternatively, the 
drugs might directly induce CAV1 expression by 
mechanisms that remain to be determined and expression 
of CAV1 in this context would favor the development 
of a more malignant phenotype. To distinguish between 
these possibilities, we first evaluated whether the low 
levels of basal CAV1 expression observed in the colon 
cancer cells (HT29(US), DLD-1 and HT9(ATCC)) and 
in the breast cancer cell line MCF7 were attributable 
to promoter methylation. Treatment of these cells 
with 5-aza dideoxycytidine (Deoxy, 5 μM), a DNA 
methylation inhibitor, increased CAV1 expression both 
in colon (Figure 1A–1C) and breast cancer cell lines 
(Figure 1D). Conversely, treatment with the histone 
deacetylase (HDAC) inhibitor, Trichostatin (50 ng/ml), 
did not significantly increase CAV1 expression and 
appeared to block the increase due to Deoxy instead 
(Figure 1). These observations indicate that basal 
expression of CAV1 is suppressed both in colon and 
breast cancer cells by DNA methylation rather than 
histone deacetylation.
Anti-neoplastic drugs increase CAV1 expression 
in colon and breast cancer cell lines
CAV1 expression increases as tumors progress 
and is associated there with increased metastasis [1, 7, 
36] and MDR [1, 2, 9, 11]. These observations, together 
with others showing that CAV1 expression is frequently 
up-regulated in response to stress situations [37–39], 
caught our attention. Given this CAV1 connection to 
a more aggressive phenotype at later stages of cancer 
disease, we reasoned that treatment with cytotoxic 
drugs using conditions that may not induce cell death 
might in fact promote CAV1 expression and thereby 
favor cancer progression. With this in mind, we 
treated colon and breast cancer cell lines with different 
chemotherapeutic agents that are routinely employed 
in cancer therapy, namely Methotrexate, Etoposide, 
Doxorubicin, Staurosporine, Taxol and Cisplatin. Note 
that for all the drugs employed, with the exception of 
Doxorubicin, cell viability was around 50-90% at the 
end of the treatment (Supplementary Table 1). We next 
evaluated CAV1 protein expression in the cancer cells. 
Subsequently, optimal conditions for CAV1 expression 
were defined by treating HT29(US) cells either with 
increasing concentrations for a specific period of time 
(Supplementary Figure 1) or a given concentration for 
varying periods of time (Supplementary Figure 2). All 
the anti-neoplastic drugs employed, increased CAV1 
expression in the colon cancer cell line HT29(US), but 
the effect was stronger with the dihydrofolate reductase 
inhibitor Methotrexate, and the topoisomerase II inhibitor 
Etoposide (Figure 2A, Supplementary Figure 1A and 1B). 
In the case of DLD-1 cells, Methotrexate and Etoposide 
were the only two drugs that significantly increased CAV1 
protein levels (Figure 2B). This was also the case for 
the breast cancer cell line MCF7 (Figure 2D), while for 
HT29(ATCC) cells, besides Methotrexate and Etoposide, 
Doxorubicin also increased CAV1 expression (Figure 2C).
Considering that the chemotherapeutic agents 
Methotrexate and Etoposide increased CAV1 expression 
in all of the cell models evaluated here, we decided to 
utilize these two agents to induce CAV1 and to identify 
the mechanism(s) by which this increase occurs.
As a first step, we determined whether up-regulation 
of CAV1 by Methotrexate or Etoposide occurred at the 
transcriptional level. To that end, we treated the colon 
cancer cell lines HT29(US) and DLD-1 with either 
Methotrexate or Etoposide for 12 and 24 h, and evaluated 
CAV1 mRNA levels by qPCR analysis. Already after 
12 h of treatment, we observed an increase in CAV1 
mRNA levels in HT29(US) (Figure 3A) and DLD-1 cells 
(Figure 3B). Thus, the anti-neoplastic drugs Methotrexate 
and Etoposide likely increase CAV1 protein levels by a 
transcriptional mechanism following promoter region 
demethylation.
Methotrexate and Etoposide induce CAV1 
promoter demethylation in colon cancer cells
To demonstrate that increased CAV1 expression 
following treatment with anti-neoplastic drugs was indeed 
associated with demethylation of the CAV1 promoter 
region, the extent of methylated DNA was determined 
in HT29(US) (Figure 4A) and DLD-1 (Figure 4B) cells 
after treatment for 48 h with Methotrexate or Etoposide 
using chromatin immunoprecipitation followed by qPCR. 
In both colon cancer cell lines, treatment with the anti-
neoplastic drugs decreased significantly methylation of the 
CAV1 promoter region (Figure 4), which likely explains, 
at least in part, the increase in CAV1 mRNA (Figure 3) 
and protein (Figure 2) levels observed following drug 
exposure.
CAV1 up-regulation requires ERK signaling and 
ROS production
In order to study the signaling pathways involved 
in CAV1 up-regulation, induced by anti-neoplastic drugs, 
cancer cells were treated with either the PI3K inhibitor 
LY294002 (10 μM), the MEK inhibitor PD98059 (50 μM) 
or with the antioxidant Trolox (2 mM), prior to addition 
of Methotrexate or Etoposide. Inhibition of MEK and pre-
treatment with Trolox, both individually precluded CAV1 
up-regulation induced by either Methotrexate or Etoposide 
in colon cancer cell lines HT29(US) (Figure 5A), DLD-
1 (Figure 5B) and HT29(ATCC) (Supplementary 
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Figure 3A), as well as in MCF7 breast cancer cells 
(Supplementary Figure 3B). LY294002 pre-treatment 
inhibited CAV1 up-regulation induced by Methotrexate 
in HT29(US) cells (Figure 5A), and by Etoposide in 
MCF7 cells (Supplementary Figure 3B), but not in any of 
the other cases. These results suggested that MEK/ERK 
activation and ROS production represent the predominant 
pathways involved in CAV1 re-expression induced by 
anti-neoplastic drugs in cancer cells.
Figure 1: CAV1 expression is suppressed by DNA methylation in cancer cell lines. Colon cancer cells (A) HT29(US), (B) 
DLD-1 and (C) HT29(ATCC) and breast cancer cells (D) MCF-7 were treated either with 5-aza dideoxycytidine (Deoxy, 1, 2.5, 5 or 
10 μM) for 72 h, Trichostatin (TSA, 50 ng/ml) for 24 h or the combination of 2.5 μM Deoxy and 25 ng/ml TSA. Cells were harvested 
and total protein extracts were separated by SDS-PAGE (50 μg total protein per lane) and analyzed by Western blotting with antibodies 
against caveolin-1 (CAV1) and β-actin. The graphs show the expression of CAV1 normalized to β-actin (mean ± SEM) of 3 independent 
experiments. Significant differences in comparison with the untreated condition (Basal) are indicated *** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05.
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Subsequently, we evaluated whether these anti-
neoplastic drugs activate ERK in DLD-1 colon cancer cells, 
using phospho-ERK specific antibodies. Methotrexate 
treatment induced three ERK 1/2-phosphorylation peaks, 
at 5 and 30 min and then again after 6-10 h of exposure 
(Supplementary Figure 4A). Alternatively, Etoposide 
induced two ERK 1/2-phosphorylation peaks, at 5 min 
and after 15 h of drug exposure (Supplementary Figure 
4B). Considering that Methotrexate and Etoposide induced 
an increase in CAV1 mRNA after 12 h of treatment, the 
Figure 2: Anti-neoplastic drugs increase CAV1 expression in colon and breast cancer cell lines. Colon cancer cells (A) 
HT29(US), (B) DLD-1, (C) HT29(ATCC) and breast cancer cells (D) MCF-7 were treated with 100 nM Methotrexate (MT), 10 μM 
Etoposide (ET), 1 μM Doxorubicin (DX), 5 nM Staurosporine (ST), 5 nM Taxol (TX) or 100 nM Cisplatin (CP) for 24 h. Cells were 
harvested and total protein extracts were separated by SDS-PAGE (50 μg total protein per lane) and analyzed by Western blotting with 
antibodies against caveolin-1 (CAV1) and β-actin. The graphs show the expression of CAV1 normalized to β-actin (mean ± SEM) of 3 
independent experiments. Significant differences in comparison with the untreated condition (Basal) are indicated *** p ≤ 0.001, ** p ≤ 0.01, 
* p ≤ 0.05.
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findings suggest that ERK1/2 activation by Methotrexate 
and the first peak of ERK1/2 activation by Etoposide are 
likely linked to transcriptional upregulation of CAV1.
By flow cytometry we then observed that 
Methotrexate induced a mild increase in intracellular ROS 
levels at 20 h in HT29(US) (Supplementary Figure 5A, 
black bars) and a more marked increase in DLD-1 cells 
(Supplementary Figure 5B, black bars), whereas Etoposide 
increased ROS levels starting at 20 h of exposure in 
HT29(US) cells (Supplementary Figure 5A, white bars) 
and after 14 h in DLD-1 cells (Supplementary Figure 5B, 
white bars).
To determine whether ERK1/2 activation resides 
upstream of ROS formation or vice-versa, we treated 
colon cancer cells with the MEK inhibitor PD98059 
prior to Methotrexate or Etoposide exposure. Inhibition 
of the MEK/ERK pathway reduced ROS induced by both 
Methotrexate and Etoposide in HT29(US) (Figure 6A) 
and in DLD-1 (Figure 6B) cell lines. Thus, MEK/ERK 
activation lies upstream of ROS formation, and both 
are required for drug-induced up-regulation of CAV1 
transcription (Figure 5).
CAV1 up-regulation induced by Methotrexate 
and Etoposide enhances cancer cell migration
CAV1 up-regulation has been linked to an increase 
in the migration of breast, colon, melanoma [12, 31] and 
endometrial cancer cells [39]. To evaluate the functional 
consequences of CAV1 re-expression induced by anti-
Figure 3: Methotrexate and Etoposide induce an increase in CAV1 mRNA levels in colon cancer cell lines. Colon cancer 
cells (A) HT29(US) and (B) DLD-1 were treated with 100 nM Methotrexate or 10 μM Etoposide for 12 and 24 h. CAV1 mRNA levels 
were evaluated by quantitative RT-PCR analysis, using β-actin as an internal control. Values obtained by analysis of three independent 
experiments are shown for CAV1 mRNA following standardization to β-actin (mean ± SEM) and after normalizing to the values obtained 
for untreated (0 h) samples. Statistically significant differences compared with the controls (time 0) are indicated ***p ≤ 0.001, **p ≤ 0.01, 
*p ≤ 0.05.
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neoplastic drugs, we silenced CAV1 with a specific 
shRNA (sh-Cav-1 (#5)) in HT29(US) and DLD-1 cells 
(Supplementary Figure 6A and 6B, respectively). Parental 
colon cancer cells or control shRNA (sh-Scramble) 
cells treated with Methotrexate or Etoposide migrated 
approximately 3 times more rapidly than untreated 
cells (Figure 7A and 7B). However, the increase in 
cell migration induced by anti-neoplastic drugs, was 
precluded by CAV1 silencing in HT29(US) (Figure 7A, 
grey bars) and DLD-1 (Figure 7B, grey bars) cells. Hence, 
Methotrexate- and Etoposide-enhanced cell migration 
depends on CAV1 re-expression in HT29(US) and DLD-1 
colon cancer cells.
Anti-neoplastic drugs increase cell migration in 
a MEK/ERK, Src kinase and ROS dependent 
manner
To determine whether the aforementioned signaling 
pathways responsible for increasing CAV1 expression 
Figure 4: Methotrexate and Etoposide induce CAV1 promoter demethylation in colon cancer cells. (A) HT29(US) and 
(B) DLD-1 colon cancer cells were treated with 100 nM Methotrexate (MT) or 10 μM Etoposide (ET) for 48 h. Genomic DNA (gDNA) 
was denatured for 10 min at 95°C and then immunoprecipitated using the anti-5-methylcytidine antibody (5mC). Affinity purified DNA 
was then evaluated using qPCR analysis, defining the enrichment levels as a percentage of the input material. Specific primers were used 
to analyze the CAV1 proximal promoter (CAV1 promoter) or negative (CSa region) and positive control regions (IAP region). Statistically 
significant differences compared with the control (Basal, black bars) are indicated ***p ≤ 0.001, **p ≤ 0.01.
Oncotarget111950www.impactjournals.com/oncotarget
were also responsible for the increase in cell migration, 
we pre-treated HT29(US) and DLD-1 cells with either 
the MEK inhibitor PD98058 or the antioxidants Trolox 
or Tiron. As anticipated, MEK/ERK inhibition precluded 
the increase in cell migration induced by Methotrexate or 
Etoposide in HT29(US) (Figure 8A) and DLD-1 (Figure 
8B) cells. Likewise, we observed the same inhibitory 
effects in Trolox pre-treated cells; however pre-treatment 
Figure 5: Effects of either PI3K or MEK inhibition as well as the antioxidant Trolox on the up-regulation of CAV1 
induced by Methotrexate and Etoposide. Colon cancer (A) HT29(US) and (B) DLD-1 cells were treated with either the 
PI3K inhibitor LY294002 (LY, 10 μM), the MEK inhibitor PD98059 (PD, 50 μM) or the vitamin E analog, Trolox (TR, 2 
mM) for 30 min before treatment with 100 nM Methotrexate (MT) or 10 μM Etoposide (ET) for 48 h. Cells were harvested 
and total protein extracts were separated by SDS-PAGE (50 μg total protein per lane) and analyzed by Western blotting with 
antibodies against CAV1 and β-actin. The graphs show the expression of CAV1 normalized to β-actin (mean ± SEM) averaged 
from 3 independent experiments. Significant differences in comparison with the untreated condition (Basal) are indicated ***p 
≤ 0.001, **p ≤ 0.05, *p ≤ 0.01.
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with the superoxide scavenger Tiron, did not affect either 
Methotrexate or Etoposide enhanced cell migration. 
Because Trolox is a membrane-bound vitamin E-analog, 
these results suggest that ROS generation at the plasma 
membrane is likely to be responsible for favoring cell 
migration.
Previous studies showed that CAV1 phosphorylation 
on tyrosine 14 is required to promote CAV1-dependent cell 
migration [12] and that Src family kinases are activated 
by ROS [15]. Thus, we treated cells with Methotrexate 
or Etoposide. As anticipated, PP2 pre-treatment blocked 
the increase in cell migration observed in both cells lines 
following treatment with either Methotrexate or Etoposide 
(Figure 8), suggesting an important role for CAV1 
phosphorylation on tyrosine 14 in cell migration induced 
by anti-neoplastic drugs.
Methotrexate and Etoposide enhance 
metalloproteinase activity via CAV1 up-
regulation
Metastasis is a complex process that involves 
degradation of the extracellular matrix, invasion of 
the stromal tissue, intravasation into the circulation, 
extravasation, migration and proliferation in other tissues 
and organs [25, 26]. The gelatinases B, MMP9 and MMP2 
are members of the matrix metalloproteinase family that 
play a critical role in cell invasion and metastasis. Thus, 
Figure 6: MEK inhibition reduces ROS production induced by Methotrexate and Etoposide. (A) HT29(US) or (B) DLD-
1 colon cancer cells (3 x 106) were seeded in 24-well plates and, after 24 h, were treated with the MEK inhibitor PD98059 
(PD, 50 μM) for 30 min, added prior to treatment with 100 nM Methotrexate for 20 h or 10 μM Etoposide for the indicated 
time periods. Cells were washed 3 times with PBS and subsequently incubated with trypsin for 5 min. Once in suspension, 
cells were loaded with the probe DHR123 (1.4 μg/ml) in RPMI media without serum for 30 min and then the reaction was 
stopped on ice. The extent of DHR123 oxidation was determined by flow cytometry. The graphs show DHR123 fluorescence 
normalized to the untreated condition (Basal) (mean ± SEM) averaged from 3 independent experiments. Significant differences 
are indicated ***p≤ 0.001, **p ≤ 0.01, *p ≤ 0.05.
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we next investigated whether Methotrexate and Etoposide 
treatments modulated metalloproteinase activity. Indeed, 
both Methotrexate and Etoposide exposure increased 
MMP9 activity in HT29(US) (Figure 9A) and DLD-1 
(Figure 9B) cells in comparison with non-treated cells. For 
MMP2 activity, a very modest increase was only detected 
in HT29(US) cells. Importantly, in both HT29(US) and 
DLD-1 cells, activation of MMP9 and MMP2 was reduced 
in cells where CAV1 expression had been silenced, in 
agreement with data reported in the literature linking 
CAV1 expression to the transcriptional upregulation of 
metalloproteinases in vascular smooth muscle cells [40] 
and cancer cells [41]. For MMP2, CAV1 silencing lead to 
a significant decrease in basal activity in HT29(US) cells 
(Figure 9).
Anti-neoplastic drugs increase cancer cell 
invasion in a manner dependent on Src family 
kinases and Rac1 activation
Because Methotrexate and Etoposide increased 
metalloproteinase activity, we investigated whether the 
treatment with anti-neoplastic drugs induced colon cancer 
cell invasion. As expected, Methotrexate and Etoposide 
Figure 7: CAV1 silencing precludes the increase in cell migration induced by Methotrexate and Etoposide in colon 
cancer cell lines. Parental, sh-Scramble and sh-CAV1 (#5) (A) HT29(US) or (B) DLD-1 cells (6 x 105) were seeded in 6 cm 
plates 24 h before treatment with 100 nM Methotrexate or 10 μM Etoposide for 48 h. Cells (2 x 105) were then seeded in 
Boyden chambers coated with fibronectin (2 μg/ml) on the lower side and allowed to migrate for 7 h (HT29(US) cells) or 5 h 
(DLD1 cells). The cells that migrated through the pores were stained and counted. Values obtained were normalized to those 
obtained for parental cells without treatment. The graphs show the averages of values from 3 independent experiments (mean 
± SEM). Significant differences are indicated **p ≤ 0.01, *p ≤ 0.05.
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enhanced invasion of HT29(US) (Figure 10A) and DLD-
1 cells (Figure 10B) in a manner dependent on Src family 
kinase activity, since pre-treatment with the Src family 
kinase inhibitor PP2 impaired cell invasion in both cases 
(Figure 10A and 10B).
In melanoma cells, CAV1 expression induces an 
increase in cell migration and invasion by the activation 
of Rac1 [31]. Based on these findings, we investigated 
in our models whether Rac1 activity was implicated in 
invasion triggered by treatment with the anti-neoplastic 
Figure 8: Effect of MEK and Src family kinase inhibition, as well as the anti-oxidants Trolox and Tiron on cell 
migration induced by Methotrexate and Etoposide. (A) HT29(US) or (B) DLD-1 cells (6 x 105) were seeded in 6 cm plates 
24 h before treatment with the MEK inhibitor PD98059 (PD, 50 μM), the Src family kinase inhibitor PP2 (1 mM), the vitamin E analog 
Trolox (TR, 2 mM) or the superoxide scavenger Tiron (Ti, 4 mM) for 30 min (PD, TR and Ti) or 1 h (PP2) before treatment with 100 nM 
Methotrexate or 10 μM Etoposide for 48 h. Cells (2 x 105) were then seeded in Boyden chambers coated with fibronectin (2 μg/ml) and 
allowed to migrate for 7 h (HT29(US) cells) or 5 h (DLD1 cells). The cells that migrated through the pores were stained and counted. 
Values were normalized to those obtained for cells without treatment (Basal). The graphs show the averages of results from 3 independent 
experiments (mean ± SEM). Significant differences are indicated ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05.
Oncotarget111954www.impactjournals.com/oncotarget
drugs. To that end, we transfected HT29(US) and DLD-1 
cells with a Rac1 dominant-negative (RacS17N-GFP) and 
observed that Rac1 activity was necessary for the increase 
in invasion of these cells induced by Methotrexate and 
Etoposide (Figure 10C and 10D). Tiam1, a GEF implicated 
in Rac1 activation downstream of CAV1 is inhibited by the 
compound NSC23766 [31]. As anticipated, pre-treatment 
with NSC23766 also blocked Etoposide-induced invasion 
by colon cancer cells (Figure 10A and 10B). Surprisingly, 
however, this inhibitor did not reduce Methotrexate-
induced invasion of either HT29(US) or DLD-1 cells 
(Figure 10A and 10B). Thus, a Tiam1-independent, but 
Rac1-dependent, pathway is likely to participate in CAV1-
enhanced invasion following Methotrexate treatment.
Figure 9: CAV1 silencing decreases metalloproteinase activity induced by Methotrexate and Etoposide in colon cancer 
cell lines. sh-Scramble and sh-CAV1 (#5) (A) HT29(US) or (B) DLD1 cells (6 X 105) were seeded in 6 cm plates 24 h before treatment with 
100 nM Methotrexate or 10 μM Etoposide for 48 h. Cells were harvested and total protein extracts were subjected to gelatin zymography. 
The graphs show the densitometric analysis of gelatinolytic activity detected at 92 kDa (pro-MMP9) and 72 kDa (pro-MMP2) averaged 
from 3 independent experiments (mean ± SEM). Significant differences are indicated, ***p≤ 0.001, **p ≤ 0.01, *p ≤ 0.05.
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Treatment with anti-neoplastic drugs increases 
cancer cell metastasis in vivo
Finally, to underscore the importance of 
these observations, we explored the effects of acute 
Methotrexate and Etoposide treatments on the metastatic 
properties of colon cancer cells in vivo. To this end we 
used a murine model of intraperitoneal carcinomatosis, 
in order to evaluate intra-abdominal dissemination of 
malignant cells (Figure 11) [42]. HT29(US) human colon 
cancer cells transduced with either (sh-Scramble) or (sh-
Cav1(#5)) containing lentivirus were treated for 48 h 
either with Methotrexate or Etoposide, washed and then 
injected intraperitoneally (1x106) into BalbC/NoD/SciD 
mice. After 12 days, the mice injected with HT29(US)
(sh-Scramble) cells, which were treated with either 
Methotrexate or Etoposide showed an increase in the 
Morton punctuation [43, 44]. After 21 days, the mice were 
euthanized and the extent of paracentesis was determined 
by counting the number of live cells in the intraperitoneal 
Figure 10: Methotrexate and Etoposide increase cancer cell invasion in a Src family kinase and Rac1 dependent 
manner. (A) HT29(US) or (B) DLD1 (6 X 105) cells were seeded in 6 cm plates 24 h before pre-treatment with either the Src family 
kinase inhibitor, PP2 (1 mM) or with the Tiam1 inhibitor, NS (NSC 23766, 100 mM) for 60 min followed by the treatment with 100 nM 
Methotrexate (MT) or 10 μM Etoposide (ET) for 48 h. (C) HT29(US) or (D) DLD1 (6 X 105) cells were transfected with GFP (white 
bars) or with the Rac1 dominant-negative, RacS17N (black bars), 24 h before the treatment with 100 mM Methotrexate (MT) or 10 μM 
Etoposide (ET) for 48 h. Then, cells (2 x 105) were seeded in Matrigel-coated chambers and allowed to invade the matrix for 24 h. The cells 
that accumulated on the lower surface of the membrane were then stained and counted. Values obtained were normalized to those obtained 
for cells without treatment (Basal). The graphs show the averages of results from 3 independent experiments (mean ± SEM). Significant 
differences are indicated, **p ≤ 0.01, *p ≤ 0.05.
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Figure 11: Ex vivo treatment of colon carcinoma cells with Methotrexate and Etoposide increases the number of CAV1-
expressing cells in ascites fluid and metastasis in vivo. (A) Schematic summarizing events in the intraperitoneal carcinomatosis 
assay: Seven week-old BalbC/NoD/SciD mice (5 mice per group) were injected intraperitoneally with 1 x 106 sh-Scramble or sh-CAV1 (#5) 
HT29(US) cells treated with 100 nM Methotrexate (MT) or 10 μM Etoposide (ET) for 48 h prior to injection. After 21 days, the animals 
were euthanized and paracentesis was analyzed. (B) The graph shows the number of viable cells in the ascitic fluid in each condition. (C) 
Representative images at 21 days post-cell injection showing the intestine, pancreas, spleen and stomach of mice injected with HT29(US) 
sh-Scramble (upper panel) or HT29(US) sh-CAV1 (#5) (lower panel) that prior to injection were either not treated (Basal) or treated with 
100 nM Methotrexate (MT) or 10 μM Etoposide (ET) for 48 h. (D) The graph shows the total mass of the solid tumors and the infiltrated 
organs (intestine, pancreas, spleen and stomach) of mice injected with HT29(US) sh-Scramble or HT29(US) sh-CAV1 (#5) that were 
previously either not treated (Basal) or treated with 100 nM Methotrexate (MT) or 10 μM Etoposide (ET) for 48 h, as well as the total 
weight of the organs in non-treated mice (NT). Significant differences are indicated, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05.
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ascitic fluid. Under basal conditions (non-treated cells), 
in mice injected with CAV1-expressing HT29(US) cells 
(HT29(US) sh-Scramble), the ascites fluid contained 
more cells than observed for mice injected with CAV1-
silenced cells (HT29(US) sh-CAV1 (#5)) (Figure 11B). 
Furthermore, in mice that were injected with HT29(US) 
sh-Scramble cells after treatment with either Methotrexate 
or Etoposide, the malignant ascites volume was increased 
(data not shown) in comparison with either non-treated 
cells or cells that did not express CAV1 (HT29(US) sh-
CAV1 (#5)) (Figure 11B).
Also the solid tumor mass was evaluated for 
each condition. For mice injected with HT29(US) cells 
expressing CAV1 (HT29(US) sh-Scramble), treated or 
not with either Methotrexate or Etoposide, the tumor mass 
associated with the intestine, pancreas, spleen and stomach 
was higher than the tumor mass generated after injection 
of cells that did not express CAV1 (HT29(US) sh-CAV1 
(#5)) (Figure 11C and 11D). Moreover, in cells that did 
not express CAV1, treatment with these anti-neoplastic 
drugs produced smaller tumors than mice injected with 
non-treated HT29(US) sh-CAV1 (#5) cells (Figure 11C 
and 11D). These results suggest that enhanced expression 
of CAV1 observed in carcinoma cells following exposure 
to chemotherapeutic drugs is necessary and sufficient to 
promote tumor cell metastasis.
DISCUSSION
CAV1 plays a dual role in the development of cancer. 
At early stages it is considered a tumor suppressor and at 
later stages it contributes to a more aggressive phenotype 
[1]. In part, CAV1 does so by modulating drug pump 
expression and function [45]. This requires extensive 
periods of exposure to drugs. For instance, incubation 
of HT29(US) cells with increasing concentrations of 
Etoposide (50 – 1000 nM) gradually increased CAV1 
levels over extended periods of time (approx. 3-6 months) 
and this increase correlated with enhanced multi-drug 
resistance (Montoya and Quest, unpublished data). These 
observations are consistent with the classic view that 
malignant cancer cell traits are acquired as a consequence 
of a long-term selection process. However, the findings 
presented here point towards the existence of mechanisms 
by which short-term (24-48 h exposure) exposure to anti-
neoplastic drugs induces changes particularly in CAV1 
expression that favor the acquisition of a more aggressive, 
metastatic phenotype. These findings are consistent with 
predictions made by the phenotype-switching model 
suggesting that rapid changes in cancer cell behavior can 
be triggered by “environmental” factors [46].
Chemotherapy remains an important and effective 
treatment for early stage cancer; however, resistance 
to conventional chemotherapeutic agents poses a 
tremendous challenge, and represents a major obstacle 
in the treatment of cancer, which may potentially lead 
to tumor relapse and failure of the therapy [47, 48]. The 
mechanisms contributing to drug resistance either reduce 
effective intracellular drug concentration and/or reduce 
sensitivity to the drugs. Here we show that the treatment 
with several anti-neoplastic drugs at generally sub-
cytotoxic concentrations induced up-regulation of CAV1. 
For Methotrexate and Etoposide, we further show that 
this increase is associated with enhanced cell migration, 
invasion and metastasis, and therefore, with a more 
malignant phenotype.
Two major types of epigenetic alterations closely 
linked to cancer are aberrant DNA methylation and 
covalent histone modifications [49]. The 5’ region of the 
caveolin-1 promoter is enriched in CpG islands that are not 
methylated in normal breast epithelial cells and express 
higher levels of CAV1; however, in breast cancer cell lines 
that do not express CAV1, this region is highly methylated 
[6]. The methylation pattern of the CAV1 promoter 
also changes according to the level of malignancy and 
metastatic potential in breast cancer tumors [50]. In 
HT29 colon cancer cells, CAV1 expression is silenced 
by treatment of the cells with butyrate, which induces 
histone hyperacetylation among other effects [51]. Thus 
both modes of regulation have been implicated in CAV1 
silencing in cancer cells. Here we show that suppression of 
basal CAV1 expression in the colon and breast cancer cells 
employed in our studies is reverted by inhibition of DNA 
methylation using 5-aza dideoxycytidine. Also, we provide 
direct evidence in DNA immunoprecipitation assays using 
methylation-specific antibodies that the CAV1 promoter 
region is demethylated upon exposure of colon cancer 
cells to Methotrexate or Etoposide.
An important objective of the present study was 
to show that although these drugs elicit their cytotoxic 
effects via distinct mechanisms when engaging tumor 
cells, they increased the expression of CAV1 even at 
sub-cytotoxic concentrations by triggering signaling 
pathways commonly associated with tumor survival and 
progression. Indeed, consistent with this view, induction of 
CAV1 expression by either Methotrexate or Etoposide was 
very effectively blocked by the MEK inhibitor (PD98059) 
and the anti-oxidant Trolox in both HT29(US) and DLD-1 
cells. However, the PI3K inhibitor LY294002, was only 
effective in blocking drug-induced CAV1 expression in 
HT29(US) cells, but not in DLD-1 cells. In HT29(US) 
cells, inhibition of the PI3K pathway using the Aurora 
kinase inhibitor A has been linked to the induction of 
autophagy [52] and this may explain why LY294002 
blocked induction of CAV1 by both Methotrexate and 
Etoposide in HT29(US) but not DLD1 cells.
All the anti-neoplastic drugs employed, increased 
CAV1 expression in the colon cancer cell line HT29(US), 
although increases were most significant for Methotrexate 
and Etoposide. These were the only two drugs that 
increased significantly CAV1 protein levels in the other 
colon cancer cell line DLD-1 and the breast cancer cell 
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line MCF7. Importantly, Methotrexate and Etoposide 
increased the mRNA and protein levels of CAV1 in colon 
and breast cancer cells. Several transcription factors 
are known to regulate the expression of CAV1 during 
cancer progression. In human lung cancer cells, CAV1 
expression is up-regulated by PEA3/E1AF and down-
regulated by Net/Elk-3 [53]. Also, activation of PPARγ 
correlates with an increase in CAV1 mRNA in breast and 
colon cancer cells [54], and RANKL up-regulates CAV1 
during osteoclastogenesis [55]. The CAV1 gene was 
identified as one of the possible target genes of NF-κB 
[56]. Therefore, CAV1 up-regulation by exposure to the 
chemotherapeutic agents Methotrexate or Etoposide (the 
drugs we characterized in greater detail here) could be 
due to activation of one or several of these transcription 
factors, and additional studies are required to define those 
involved.
Methotrexate and Etoposide increased mRNA and 
protein levels of CAV1 in colon and breast cancer cells 
through activation of the MEK/ERK pathway and the 
subsequent increase in ROS levels. In neuronal cells, 
Etoposide and Doxorubicin increased ROS via FOXO3 
activation, which alone suffices to trigger bursts of ROS 
and then apoptosis [22]. In primary human lung cells, 
TIG-3, via the Ras/MEK pathway, induced the expression 
of superoxide-generating NADPH oxidases (Nox), such 
as Nox4, leading to an increase in intracellular ROS 
levels [57]. Also, in monocytic cells, stimulation of the 
Toll-like receptor 4 (TLR4) and 2 (TLR2) induces the 
IRAK-ERK pathway that connects to p67 phox-Nox2 
for ROS generation, which regulate IL-1β transcription 
and processing [58]. Taken together, these observations 
suggest that Nox family members could be involved in 
the mechanisms that up-regulate CAV1 expression after 
exposure to anti-neoplastic drugs. This is an intriguing 
possibility that needs to be addressed in future studies.
Upon upregulation, CAV1 can be phosphorylated on 
tyrosine 14 (Y14), by Src-family kinases. Phosphorylation 
of CAV1 at this site has been linked to increased 
anchorage-independent growth and cell migration 
by a mechanism dependent on Grb7 [59]. Matrix 
metalloproteinase activation has been described in large 
Figure 12: Working model summarizing the main findings described in this study identifying the mechanisms by 
which cytotoxic drugs induce CAV1 expression. Initially, CAV1 expression is repressed by methylation in the gene promoter region 
in tumor cells. Exposure to the anti-neoplastic drugs Methotrexate or Etoposide induces promoter demethylation that increases transcription 
and expression of CAV1 that is is mediated by ERK activation and ROS production. Likewise, ROS are shown to promote Src family 
kinase-dependent CAV1 phosphorylation that may lead to Rac1 and metalloproteinase activation, as well as increased migration, invasion 
and metastasis.
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cell lung carcinoma, where elevated CAV1 expression 
correlates with advanced stages of lung cancer as well 
as increased MMP9/MMP2 expression and activity. 
Knockdown of CAV-1 in H460 and 9D5 cells decreases 
the protein levels, as well as MMP9/MMP2 activity 
[60]. Moreover, cell invasion [61] and expression of the 
matrix metalloproteinase genes MMP1 and MMP2 are 
significantly enhanced by CAV1 in glioblastoma cells 
[62]. Here we show that pre-treatment with an inhibitor of 
the Src-family kinases (PP2) blocked the increase in cell 
migration and invasion in colon and breast cancer cells 
and that CAV1 silencing decreased particularly MMP9 
activity induced by the anti-neoplastic drugs. Available 
evidence indicates that cytosolic ROS activate Src-family 
kinases [63], which may phosphorylate CAV1 [64] to 
enhance cell migration. Additional targets of cytosolic 
ROS are the Focal Adhesion Kinase (FAK) [65] and 
structural proteins such as β-actin [66]. Both Src and FAK 
are initiators of focal adhesion formation in adherent cells, 
which upon activation favor cell spreading and migration 
[67].
Further studies are required to define the 
mechanisms by which the increase in ROS production 
induced by Methotrexate or Etoposide promote cell 
migration in a CAV1-dependent manner. However, given 
that ROS activate Src-family kinases and the inhibitor 
PP2 reduces CAV1-enhanced migration, these kinases 
are likely to be involved. Moreover, we have previously 
shown that CAV1 phosphorylation on tyrosine-14 leads 
to activation of a novel Rab5-Tiam1-Rac1 signalng 
axis important in migration and invasion of cancer cells 
[31]. Consistent with the possibility that this pathway 
may be relevant here, transfection with the dominant 
negative Rac(S17N) mutant completely abolished 
Methotrexate- and Etoposide-induced DLD-1 invasion. 
Rather surprisingly, however, while the Tiam-1/Trio 
inhibitor (NSC23766) effectively reduced invasion of 
both HT29(US) and DLD-1 cells observed after Etoposide 
exposure, this was not the case following Methotrexate 
treatment, indicating that other Rac1 GEFs are likely to be 
involved downstream of CAV1.
Augmented CAV1 expression is frequently linked 
to enhanced metastatic potential of cancer cells (reviewed 
in [1, 7, 36]). As anticipated, knock-down of CAV1 
efficiently reduced infiltation of several organs (liver, 
kidney, spleen) by HT29(US) cells in the carcinomatosis 
assay. However, the treatment with Methotrexate or 
Etoposide prior to injection of cells did not increase 
metastasis in this manner. Thus, we also evaluated 
accumulation of cells in the ascites fluid, which is a more 
sensitve marker and observed for Methotrexate treated 
cells a highly significant increase in cell number, while 
for Etoposide a trend was apparent but differences to 
controls were not significant (Figure 11B). It is interesting 
to speculate here that the pronounced difference observed 
for Methotrexate may relate to the increased relevance of 
PI3K activation in CAV1 induction in HT29(US) cells 
(Figure 5A).
Augmented CAV1 expression has been associated 
previously with progression towards a more aggressive 
cancer phenotype, for instance for prostate cancer and 
melanomas [38, 68–70], although in those cases the 
precise mechanisms involved were not defined. The 
novelty of the findings reported here resides in showing 
that exposure of cancer cells to anti-neoplastic drugs at 
sub-cytotoxic concentrations may induce signaling events 
and changes in transcription that favor a more aggressive 
metastatic phenotype in the absence of selection for drug-
resistance. Whether similar mechanisms are relevant in 
cases where CAV1 upregulation occurs in the absence of 
drug exposure remains to be defined.
We propose the working model shown in Figure 
12, which is consistent with most of the data shown 
here. In breast and colon cancer cells, CAV1 expression 
is repressed by methylation; however, exposure to 
Methotrexate or Etoposide, and presumably other 
cytotoxic drugs, induces CAV1 transcription, likely via 
promoter demethylation, and CAV1 expression mediated 
by ERK phosphorylation/activation and ROS production. 
Additionally, ROS are shown to promote Src-family 
kinase activation, CAV1 phosphorylation on Y14 and 
downstream Rac1 activation, which is indicated here 
as being responsible for metalloproteinase activation, 
increased migration, invasion and metastasis.
MATERIALS AND METHODS
Materials
Rabbit polyclonal anti-caveolin-1 (Transduction 
Laboratories, Lexington, KY, USA), anti-actin (R&D 
Systems, Minneapolis, MN, USA), goat polyclonal anti-
MMP2 and anti-MMP9 (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), antibodies were used as indicated by 
the manufacturers. Goat anti-rabbit and goat anti-mouse 
IgG antibodies coupled to horseradish peroxidase (HRP) 
were from Merck-Millipore (Billerica, Massachusetts, 
USA) and KPL Laboratories (Washington DC, USA), 
respectively. The anti-neoplastic drugs Methotrexate, 
Etoposide, Doxorubicin, Staurosporine and Cisplatin 
were from Calbiochem (La Jolla, CA, USA), while 
Taxol was from Molecular Probes (Eugene, OR, USA). 
CpG methyltransferase was from New England BioLabs 
(Ipswich, MA, USA). The ECL chemiluminescent 
substrate and the BCA protein determination kit were 
from Pierce (Rockford, IL, USA). The Plasmid Midi Kit 
was from Qiagen (Valencia, CA, USA). The Quant-iT™ 
dsDNA Assay Kit was from Broad Range (Invitrogen 
(Carlsbad, CA, USA). Human fibronectin was from 
Becton Dickinson (San Jose, CA, USA). Hygromycin 
was from Calbiochem (La Jolla, CA, USA). Fetal bovine 
serum (FBS) was from Biological Industries (Cromwell, 
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CT, USA). Cell culture media and antibiotics were from 
GIBCO (Invitrogen, Carlsbad, CA, USA). LY294002, 
PD98059 and Trolox were from Enzo Life Sciences 
(Farmingdale, NY, USA). The Histostain Bulk kit was 
from Zymed Laboratories (San Francisco, CA, USA) 
and the EZ DNA Methylation kit from Zymo Research 
(Orange, CA, USA).
Cell culture
The colon cancer cell line HT29(US) is a metastatic 
derivative of HT29(ATCC) cells from ATCC (ATCC 
HTB-38) that we have employed previously [31, 71]. 
HT29(US) and HT29(ATCC) cells were cultured in high-
glucose DMEM, DLD-1 colon cancer cells in RPMI and 
MCF7 breast cancer cells in DMEM-F12. All media 
were additionally supplemented with 10% FBS, 100 U/
ml of penicillin and 100 μg/mL of streptomycin sulfate. 
Cells were cultured at 37°C in a humidified atmosphere 
containing 5% CO2.
CAV1 shRNA lentiviral infection
Lentiviral transduction particles encoding for 
shRNA against CAV1 (sh-Cav-1 (#5)) and with a shRNA 
control (sh-Scramble) were obtained from the Broad 
Institute, Cambridge, USA and employed as previously 
described (Urra et al., 2012). Briefly, HEK293T cells were 
transfected with plasmids for the vector (pLKO.1puro), 
packaging (Δ8.9–pCMVΔR8.9 and vsv-g–pHCMV-G) and 
the corresponding shRNA against CAV1 (shCav-1(#5)) and 
luciferase (shLuc) using the Superfect® Reagent (Qiagen®, 
Valencia, USA). Cell supernatants were recovered after 
24 h, aliquoted and stored frozen at −20°C. The shRNA 
sequences tested were: GCTTCCTGATTGAGATTCAGT 
(shCav-1(#5)) and CGCTGAGTACTTCGAA ATGTC 
(shLuc). Cells (5 x 105) were plated and transduced with 
lentivirus containing the indicated shRNAs and selected 
in puromycin-containing (1 μg/mL) cell culture medium 
for 1 week.
Treatments with methylation and acetylation 
inhibitors
Cells (5 x 105) were seeded in 60 mm plates 24 h 
before treatment with the methylation inhibitor, 5-aza 
dideoxycytidine (1, 2, 5, 10 μM) for 72 h or with the 
acetylation inhibitor, Trichostatin (50 ng/ml) for 24 h. 
Cells were also treated with a combination of 2.5 μM 
5-aza dideoxycytidine (72 h) and 25 ng/mL Trichostatin 
for 24 h.
Methylated DNA immunoprecipitation (MedIP)
MedIP was performed as has been described 
previously [72, 73] Briefly, genomic DNA (gDNA) was 
isolated from cell samples following overnight Proteinase 
K treatment in lysis buffer (20 mM Tris pH 8.0, 4 mM 
EDTA, 20 mM NaCl and 1% SDS) by phenol-chloroform 
extraction and subsequent ethanol precipitation in the 
presence of RNase. Purified gDNA was then sonicated 
to produce fragments of ~400 bp. Fragmented gDNA 
(4 μg) was denatured for 10 min at 95°C and then 
immunoprecipitated overnight at 4°C with 4 μg of anti-
5-methylcytidine (Eurogentec) antibody in a final volume 
of 500 μl of IP buffer (10 mM sodium phosphate pH 
7.0, 140 mM NaCl, 0.05% Triton X-100). The mixture 
was incubated with 40 μl of dynabeads anti-mouse IgG 
(Invitrogen #11202D) for 2 h at 4°C and washed twice 
with 700 μl of IP buffer. Dynabeads were then treated with 
7 μl of proteinase K (10 mg/ml) in 250 μl of Digestion 
buffer (50 mM Tris pH 8.0, 10 mM EDTA and 0.5% 
SDS) for 3 h at 50°C. Immunoprecipitated DNA was 
recovered by phenol-chloroform extraction followed by 
ethanol precipitation using glycogen as a carrier. Purified 
DNA was then evaluated using qPCR analysis, defining 
the enrichment levels as percentage of input material. 
Distinct primers were used to analyze the CAV1 proximal 
promoter (CAV1: Forward-GCCTTGGTTGCCCATACT; 
Reverse-CTAGGCACATCCCCAAGGT) or negative 
(CSa: Forward-ACATATCCAAGGACGTGTAA; 
Reverse-AGCTAACTCCAACTTTCCAG) and positive 
(IAP: Forward-TTGGGACAGTCCAAGTCTT; Reverse-
CCCTTCACCACCTTCTTGAT) control regions.
Western blotting
Cells were rinsed and harvested in ice-cold PBS 
containing 1 mM orthovanadate, 10 μg/ml benzamidine, 
2 μg/ml antipain, 1 μg/ml leupeptin and 1 mM 
phenylmethyl-sulphonylfluoride (Ova-BAL-PMSF). Cells 
were then centrifuged at 3000 x g for 2 minutes at 4°C 
and the respective cell pellets were lysed by sonication in 
extraction buffer (Hepes 20 mM pH 7.4, NP40 0.1% and 
SDS 0.1% plus Ova-BAL-PMSF). Protein concentrations 
in extracts was determined using the BCA protein assay 
kit. Protein samples were separated by SDS-PAGE (50 
μg per lane), transferred to nitrocellulose, blocked in 
PBS containing 5% non-fat milk and probed overnight 
at 4°C with anti-CAV1 antibody (1:5000) diluted in PBS 
containing 5% gelatin and 1% Tween-20. Protein loading 
in each lane was assessed by probing with an anti-β-actin 
antibody (1:5000). Goat anti-rabbit IgG antibodies coupled 
to horseradish peroxidase were used to detect bound first 
antibodies by EZ-ECL. Protein bands were quantified by 
densitometric analysis using the ImageJ 1.34s software 
(available from NIH at http://rsb.info.nih/ij/).
Analysis of mRNA levels by quantitative real 
time qPCR
Total RNA was isolated with the reagent TriZOL® 
reagent (Ambion, Life Technologies), following 
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instructions provided by the manufacturer. Quality of 
RNA samples was corroborated by electrophoresis on 
1% agarose gels and the concentration was determined 
using a Nanoquant infinite M200Pro instrument. RNA 
was treated with RNAase-free DNAase and employed 
as template for cDNA synthesis using M-MLV Reverse 
Transcriptase (Promega). PCR-amplification of CAV1 
cDNA was performed combining the forward primer 
5´-TGGTTTTACCGCTTGCTGTCTG with the 
reverse primer 5´-GCAAGTTGATGCGGACATTGCT. 
For amplification of β-actin cDNA used as 
a housekeeping control, the forward primer 
5´-TGGCACCCAGCACAATGAAGA and reverse primer 
5´-GAAGCATTTGCGGTGGACGAT-3´) were used. 
Primers were designed using Mx-Pro – Mx3000P v4.10 
software.
Real-time PCR was performed using the Stratagene 
Mx3000p Real-Time PCR System and the Brilliant II 
SYBR Green Master Mix qPCR kit with 2 μl template 
cDNA in a final volume of 20 μl. The reaction cycle 
consisted of a first step for 10 min at 95°C followed by 
40 cycles of consecutive 15-second steps at 95°C, 60°C 
and 72°C. Fluorescence emitted at 72°C was measured 
at the end of each cycle. After completion of all the 
amplification cycles, a melting curve analysis was run. 
DNA was quantified using the qPCR instrument Mx3000P 
(Agilent Technologies) and the results were analyzed with 
the MxPro v4.1 d software (Agilent Technologies).
ROS determination by flow cytometry
Cells (3 x 104) were seeded in 24-well plates 
24 h before pre-treatment with 50 μM MEK inhibitor 
PD98059 (Enzo life science, BML-EI360-0005) for 30 
min, followed by treatment with 100 nM Methotrexate 
for 20 h or 10 μM Etoposide for 0,16, 20, 22 or 24 h. 
Cells were washed 3 times with PBS and incubated with 
trypsin for 5 min. In suspension, the cells were loaded 
with 1.4 μg/ml DHR 123 (Invitrogen, D23806) in RPMI 
media without serum for 30 min at 37°C. The reaction was 
stopped on ice. Oxidation of DHR 123 to Rhodamine 123 
was determined by flow cytometry (FACSCanto, Beckton 
Dickinson) at 515 nm.
Migration and invasion assays
Cell migration was evaluated in Boyden Chamber 
assays (Transwell Costar, 6.5-mm diameter, 8-mm pore 
size), whereas invasion was evaluated in Matrigel assays 
(BD Biosciences, 354480), as reported previously [31].
Metalloproteinase activity using zymography 
assays
Conditioned media from DLD1 and HT29(US) cells 
treated with 100 nM Methotrexate or 10 μM Etoposide 
for 48 h and afterwards serum-starved during 16 h were 
analyzed by zymography to determine the enzymatic 
activity of MMP-2 and MMP-9. For zymography 
experiments cell extracts were separated in 10% 
polyacrylamide gels copolymerized with gelatin (1 mg/
ml). Samples (35 μg protein) were incubated for 30 min 
in sample buffer 5X (0.4M TrisHCl (pH 6.8) containing 
5% sodium dodecyl sulfate (SDS), 20% glycerol, 0.03% 
bromophenol blue) under non-reducing conditions at room 
temperature. As an internal MW standard, we used 20 ng 
each of the pure latent and active forms of MMP-2 and 
MMP-9 (Chemicon, Temecula, CA). After electrophoresis, 
gels were incubated in 2.5% Triton X-100 for 30 minutes 
at room temperature and then for 24 h in metalloproteinase 
test buffer (150 mM Tris-HCl (pH 7.5), 150 mM NaCl, 
5 mM CaCl2, 0.02% NaN3) at 37°C. Gels were fixed 
and stained in Coomassie blue R 250 for 3 h and rinsed 
overnight in distilled water. Gelatinase activity was 
identified as clear bands against a blue background [74].
Animal studies
Bioethics statement
All animal experiments were conducted in 
accordance with the guidelines of CONICYT, Chile 
and approved by the Bioethics Committee of Fundación 
Ciencia & Vida. Balb C NoD SciD mice from the Jackson 
Laboratory were maintained under specific pathogen-free 
conditions and used at 6–8 weeks of age. To generate 
intraperitoneal carcinomatosis, 1 x 106 HT29(US) sh-
Scramble or sh-CAV1(#5) cells were treated with 100 nM 
Methotrexate (MT) or 10 μM Etoposide (ET) for 48 h. 
Then, cells in 100 μl saline solution were injected into the 
intraperitoneum of Balb C NoD SciD mice. Experiments 
involved 6 groups with 5 mice per group; (1) sh-Scramble 
basal, (2) sh-Scramble MT, (3) sh-Scramble ET, (4) sh-
CAV1 (#5) basal, (5) sh-CAV1 (#5) MT, (6) sh-CAV1 (#5) 
ET. Between days 18-20 post-injection, the animals were 
evaluated according to the behavior punctuation scheme 
[43, 44]. After 21 days, the animals in groups (2) and (3) 
showed delays in their movements and appeared depressed 
with higher Morton Punctuation [43]. For these reasons, 
all mice in the different groups were euthanized at day 
21 and evaluated for malignant paracentesis by counting 
the number of live cells in the ascites fluid. Solid tumor 
masses localized in spleen, pancreas, liver and kidney 
tissue, were removed and fixed in 10% formalin to 
visualize and determine total tumor mass.
Statistical analysis
All data are expressed as mean ± standard error 
of mean (SEM) of three independent experiments. Data 
were analyzed using the unpaired t-test. Significance (p-
value) was set at the nominal level of p<0.05 or less. All 
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data were processed using INSTAT v. 3.05 (GraphPad 
Software, San Diego, USA, http://www.graphpad.com).
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